Nymox Pharmaceutical Corporation
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $3.4M | $5.2M |
| FY2020 | — | $2.1M | $3.6M |
| FY2021 | — | $-506.0K | $830.0K |
| FY2022 | — | $-482.0K | — |
| FY2023 | — | $-3.2M | — |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $3.4M | $5.2M |
| FY2020 | — | $2.1M | $3.6M |
| FY2021 | — | $-506.0K | $830.0K |
| FY2022 | — | $-482.0K | — |
| FY2023 | — | $-3.2M | — |